Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease

Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals

(2017) Marcela Krečmerová   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years

(2017) et al.   MOLECULES

Novel Levodopa Formulations for Parkinson’s Disease

(2016) Maria Eliza Freitas et al.   CNS DRUGS

Studies on a new potential dopaminergic agent:in vitroBBB permeability,in vivobehavioural effects and molecular docking evaluation

(2015) Viviana De Caro et al.   JOURNAL OF DRUG TARGETING

Potential transbuccal delivery ofl-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue

(2014) Anna Lisa Scaturro et al.   DRUG DELIVERY

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum

(2014) Gregory Porras et al.   Scientific Reports

Continuous Drug Delivery in Parkinson’s Disease

(2013) Marina Senek et al.   CNS DRUGS

Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems

(2013) Yeon Hong Lee et al.   EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS

Cytochrome P450-activated prodrugs

(2013) Paul R Ortiz de Montellano   Future Medicinal Chemistry

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease

(2013) Peter A. LeWitt et al.   MOVEMENT DISORDERS

Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine

(2013) Lauri Peura et al.   PHARMACEUTICAL RESEARCH

Designing prodrugs for the treatment of Parkinson's disease

(2012) Piera Sozio et al.   Expert Opinion on Drug Discovery

Shuttle-Mediated Drug Delivery to the Brain

(2011) Morteza Malakoutikhah et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment

(2011) Antonio Di Stefano et al.   CURRENT PHARMACEUTICAL DESIGN

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

(2011) David Brooks   Neuropsychiatric Disease and Treatment

Tyrosine hydroxylase and regulation of dopamine synthesis

(2010) S. Colette Daubner et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as l-DOPA prodrugs

(2010) Gianfabio Giorgioni et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of l-dopa amide derivatives as potential prodrugs for the treatment of Parkinson’s disease

(2010) Tao Zhou et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Simultaneous determination of l-dopa and its prodrug (S)-4-(2-acetamido-3-ethoxy-3-oxopropyl)-1,2-phenylene diacetate in rat plasma by high-performance liquid chromatography–tandem mass spectrometry and its application in a pharmacokinetic study

(2010) Weizhe Jiang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Current Prodrug Design for Drug Discovery

(2009) Pei-Wen Hsieh et al.   CURRENT PHARMACEUTICAL DESIGN

Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain

(2009) Nunzio Denora et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

New drug delivery strategies for improved Parkinson's disease therapy

(2009) Antonio Di Stefano et al.   Expert Opinion on Drug Delivery

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY

Prodrug Approaches for CNS Delivery

(2008) Jarkko Rautio et al.   AAPS Journal

Design, Synthesis and Biological Evaluation of Glutathione Peptidomimetics as Components of Anti-Parkinson Prodrugs

(2008) Swati S. More et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prodrugs: design and clinical applications

(2008) Jarkko Rautio et al.   NATURE REVIEWS DRUG DISCOVERY

Levodopa for the Treatment of Parkinson's Disease

(2008) Peter A. LeWitt   NEW ENGLAND JOURNAL OF MEDICINE

Galactosylated dopamine enters into the brain, blocks the mesocorticolimbic system and modulates activity and scanning time in Naples high excitability rats

(2007) L.A. Ruocco et al.   NEUROSCIENCE